Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
In response to the COVID-19 pandemic, nirmatrelvir/ritonavir was approved as the first per os treatment to prevent severe disease progression. This study explores patients' self-management of nirmatrelvir/r and its impact on their long-term medications, and their experience of the information provided by pharmacists and physicians. Adults receiving nirmatrelvir/r from September 2022 to March 2023 were interviewed via a semistructured telephone survey. Sociodemographic, clinical data, and experience with nirmatrelvir/r and cotreatments were collected and analyzed descriptively. Of the 281 patients receiving nirmatrelvir/r, 100 (36%) participated in this study. Ninety (90%) adhered to nirmatrelvir/r, while 5 (5%) reported early discontinuation and 5 (5%) increased time between dosages. Information gaps regarding side effects, risks, benefits, and mechanisms of action were identified. Due to interactions with nirmatrelvir/r, 43% (n = 43/85) of cotreatments were temporarily interrupted, and 13% (n = 11/85) of doses were adjusted. Patient management of nirmatrelvir/r and cotreatments was successful, but satisfaction toward nirmatrelvir/r information could be improved. This study highlights the importance of ongoing efforts to ensure communication strategies, patient education, and interprofessional collaboration in providing treatments with drug-drug interactions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078955 | PMC |
| http://dx.doi.org/10.1177/23743735251342126 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protracted SARS-CoV-2 Infection in B-cell Depleted Patients: Immunologic andiral Characteristics and Response to Dual and Extended Antiviral Therapy.
Clin Infect Dis
July 2025
Harvard Medical School, Boston, MA, United States.
Background: Immunocompromised patients remain at risk for protracted SARS-CoV-2 infections with persistent viral shedding that could pose a wider public health risk. The optimal therapeutic strategy remains unknown.
Methods: We describe a sequential case series of immunocompromised adults with protracted SARS-CoV-2 infection who received dual/extended antiviral therapy (median 23d nirmatrelvir/r; 8d remdesivir).
Patient Experiences With Nirmatrelvir/Ritonavir for COVID-19 in a Collaborative Care Model: A Cross-Sectional Study on Self-Management, Information, and Medication Impact.
J Patient Exp
May 2025
Institute of Pharmaceutical Sciences of Western Switzerland University of Geneva, University of Lausanne, Geneva, Switzerland.
In response to the COVID-19 pandemic, nirmatrelvir/ritonavir was approved as the first per os treatment to prevent severe disease progression. This study explores patients' self-management of nirmatrelvir/r and its impact on their long-term medications, and their experience of the information provided by pharmacists and physicians. Adults receiving nirmatrelvir/r from September 2022 to March 2023 were interviewed via a semistructured telephone survey.
View Article and Find Full Text PDFCost-effectiveness Analysis of Nirmatrelvir/Ritonavir for COVID-19 Among Individuals at High Risk: A Modeling Study.
Open Forum Infect Dis
April 2025
Center for Infection and Molecular Medicine, Amsterdam University Medical Center, Location AMC, University of Amsterdam, Amsterdam, the Netherlands.
Background: To prevent severe disease, nirmatrelvir/ritonavir (nirmatrelvir/r) is administered to individuals infected with SARS-CoV-2 who are at high risk, and it is currently priced at approximately $1375 in the Netherlands. We aim to evaluate the health outcomes and cost-effectiveness of nirmatrelvir/r among patients with high risk of severe disease.
Methods: We used a decision-analytic model parameterized with clinical and health care utilization data from individuals at high risk who were infected with SARS-CoV-2 between September 2021 and November 2023.
Efficacy and Safety of Sotrovimab Versus Oral Antiviral for Early Treatment in High-Risk Patients in Omicron Era: A Multicenter Retrospective Study.
Pathogens
February 2025
Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", 80131 Napoli, Italy.
Introduction: High-risk patients with COVID-19 benefit from early treatment to prevent severe outcomes. Sotrovimab, a monoclonal antibody, and oral antivirals such as nirmatrelvir/ritonavir and molnupiravir have been used for early intervention, but their comparative efficacy and safety, particularly during the Omicron-dominant phase, require further evaluation.
Methods: A multicenter, retrospective study performed in southern Italy including all adult patients who received early antiviral treatment (sotrovimab or nirmatrelvir/r or molnupiravir) between January 2022 and February 2024 (omicron phase).
Antiviral Use in Mild-to-Moderate SARS-CoV-2 Infections during the Omicron Wave in Geriatric Patients.
Viruses
May 2024
Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland.
(1) Background: Geriatric patients are at high risk of complications of Coronavirus disease-2019 (COVID-19) and are good candidates for antiviral drugs. (2) Methods: A retrospective study of electronic health records (EHRs) aiming to describe antiviral (nirmatrelvir and ritonavir (nirmatrelvir/r) or remdesivir) use, drug-drug interactions (DDIs) and adverse drug reactions (ADRs) in elderly patients (75 and over), hospitalized with mild-to-moderate COVID-19 between July 2022 and June 2023. (3) Results: Out of 491 patients (mean age: 86.
View Article and Find Full Text PDF